ES2153373T3 - Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central. - Google Patents

Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.

Info

Publication number
ES2153373T3
ES2153373T3 ES93304102T ES93304102T ES2153373T3 ES 2153373 T3 ES2153373 T3 ES 2153373T3 ES 93304102 T ES93304102 T ES 93304102T ES 93304102 T ES93304102 T ES 93304102T ES 2153373 T3 ES2153373 T3 ES 2153373T3
Authority
ES
Spain
Prior art keywords
tienobenzodiazepin
disorders
derivatives
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93304102T
Other languages
English (en)
Spanish (es)
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Application granted granted Critical
Publication of ES2153373T3 publication Critical patent/ES2153373T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES93304102T 1992-05-29 1993-05-26 Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central. Expired - Lifetime ES2153373T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2153373T3 true ES2153373T3 (es) 2001-03-01

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93304102T Expired - Lifetime ES2153373T3 (es) 1992-05-29 1993-05-26 Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.

Country Status (21)

Country Link
EP (1) EP0582368B1 (env)
JP (1) JP3219541B2 (env)
CN (1) CN1043994C (env)
AT (1) ATE198891T1 (env)
AU (1) AU668159B2 (env)
CA (1) CA2097016A1 (env)
CZ (1) CZ282783B6 (env)
DE (1) DE69329887T2 (env)
DK (1) DK0582368T3 (env)
ES (1) ES2153373T3 (env)
FI (1) FI101538B (env)
GR (1) GR3035587T3 (env)
HU (1) HU218278B (env)
IL (1) IL105827A (env)
MX (1) MX9303124A (env)
MY (1) MY109943A (env)
NO (1) NO305125B1 (env)
NZ (1) NZ247703A (env)
PT (1) PT582368E (env)
RU (1) RU2125574C1 (env)
TW (1) TW268005B (env)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
EP0932407A4 (en) * 1996-03-25 2002-04-24 Lilly Co Eli TECHNIQUE FOR TREATING MIGRAINE PAIN
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
IL126064A0 (en) * 1996-03-25 1999-05-09 Lilly Co Eli Method for treating pain
TR199900639T2 (xx) 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
RU2185383C1 (ru) * 2001-05-22 2002-07-20 Институт молекулярной генетики РАН ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CA2882454C (en) * 2012-08-21 2020-08-11 Matthew Garrett DONAHUE Haptens of olanzapine
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
EP2888263B1 (en) 2012-08-21 2018-05-09 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
EP3305784B1 (en) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptens of quetiapine for use in immunoassays
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (env) * 1972-04-04 1975-11-28 Wander Ag Dr A
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
US4061752A (en) * 1975-08-06 1977-12-06 Sandoz Ltd. 6-Piperazino-11-methylene-dibenzazepines[b,e]
DE2641378A1 (de) * 1975-09-24 1977-04-07 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
CH624682A5 (env) * 1976-11-10 1981-08-14 Sandoz Ag
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ282783B6 (cs) 1997-10-15
IL105827A (en) 1997-02-18
JP3219541B2 (ja) 2001-10-15
CA2097016A1 (en) 1993-11-30
CN1085903A (zh) 1994-04-27
MY109943A (en) 1997-10-31
FI932445L (fi) 1993-11-30
DK0582368T3 (da) 2001-02-05
IL105827A0 (en) 1993-09-22
RU2125574C1 (ru) 1999-01-27
NZ247703A (en) 1995-07-26
CZ102493A3 (en) 1993-12-15
EP0582368A1 (en) 1994-02-09
AU668159B2 (en) 1996-04-26
CN1043994C (zh) 1999-07-07
FI101538B1 (fi) 1998-07-15
AU3980793A (en) 1993-12-02
HU9301579D0 (en) 1993-09-28
ATE198891T1 (de) 2001-02-15
NO931917D0 (no) 1993-05-26
DE69329887D1 (de) 2001-03-01
NO931917L (no) 1993-11-30
FI101538B (fi) 1998-07-15
FI932445A0 (fi) 1993-05-28
JPH0687862A (ja) 1994-03-29
GR3035587T3 (en) 2001-06-29
PT582368E (pt) 2001-05-31
HUT66180A (en) 1994-09-28
MX9303124A (es) 1993-11-01
EP0582368B1 (en) 2001-01-24
TW268005B (env) 1996-01-11
DE69329887T2 (de) 2001-05-23
NO305125B1 (no) 1999-04-06
HU218278B (en) 2000-07-28

Similar Documents

Publication Publication Date Title
CO4440628A1 (es) Derivados de pirimidina condensados con un anillo heteroci- clico
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
MX9704777A (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2124612T3 (es) Dihidrodibenzo(b,f)azepinas, substituidas, metodo para su preparacion, su utilizacion en el tratamiento de diversos trastornos del sistema nervioso central y composiciones farmaceuticas que las contienen.
MX9303124A (es) Compuestos organicos de benzodiazepina, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
GT198304062A (es) Derivado epimerico de azahomoeritromicina a e intermedios del mismo
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
ES2121896T3 (es) Derivados de acido hidroxamico como inhibidores de colagenasa.
MX9401315A (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
MX9302448A (es) Derivados iminicos ciclicos, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
CO4440626A1 (es) Amidas terapeuticas
ES2165485T3 (es) Compuestos de o-carbamoil-(d)-fenilalaninol y procedimiento para preparar los mismos.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
ES2165360T3 (es) Cicloalquenos y cicloalcanos 1,3-sustituidos como agentes del sistema nervioso central.
ES2082024T3 (es) Oximas y aminas azabiciclicas y azaciclicas utiles como agentes colinergicos y sus sales farmaceuticamente aceptables.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2123873T3 (es) Pirrolocarbazol.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
ES2078019T3 (es) Amidas de alcanoil l-carnitina con aminoacidos y composiciones farmaceuticas que las contienen para promover regeneracion del tejido nervioso, inhibir degeneracion neuronal, mejorar el proceso de aprendimiento y memoria y para el tratamiento de coma.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582368

Country of ref document: ES